Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00276159 · OUTCOME

Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies · Source last updated 2019-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to Week 12

What was measured

Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (\> or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = \<5% blasts with hematopoietic recovery (absolute neutrophil count \>500) at 4 weeks.

Analysis population: Includes patients receiving at least 12 doses of 852A study drug.

Groups in this outcome

852A Treatment

Patients receiving at least 12 doses of 852A.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
852A Treatment6

Reported measurements

Stable Disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
852A Treatment1Not reportedNot reportedNot reportedNot reported
Partial Response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
852A Treatment1Not reportedNot reportedNot reportedNot reported
Progressive Disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
852A Treatment4Not reportedNot reportedNot reportedNot reported
Complete source fields
anticipated Posting Date
2009-12
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Stable Disease
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Partial Response
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Progressive Disease
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (\> or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = \<5% blasts with hematopoietic recovery (absolute neutrophil count \>500) at 4 weeks.
groups
  1. description
    Patients receiving at least 12 doses of 852A.
    id
    OG000
    title
    852A Treatment
param Type
NUMBER
population Description
Includes patients receiving at least 12 doses of 852A study drug.
reporting Status
POSTED
time Frame
Up to Week 12
title
Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice